Amerikaanse aandelen « Terug naar discussie overzicht

ADVENTRX PHARMACTL ANX

425 Posts, Pagina: « 1 2 3 4 5 6 ... 16 17 18 19 20 21 22 » | Laatste
[verwijderd]
0
I see at least three reasons to buy Adventrx currently

1. The company is trading below its net cash position

Adventrx had cash of $46 million and 47 million shares outstanding as of March 31st. This creates net cash of $0.97 per share.

2. Insiders have been buying shares lately

Director David A. Ramsay purchased 100,000 shares during month of May. Brian M. Culley purchased 34,500 shares during the month of March. Mr. Culley joined Adventrx in December 2004 and currently serves as chief executive officer, a position he has held since February 2010, and is also a member of board of directors.

3. The company has analyst price target of $1.46 per share

Edison Investment Research initiated coverage on Adventrx on May 25th 2012. At their investment report they wrote:

We value Adventrx at $80m, or $1.46 per share, based on a sum-of-the-parts DCF valuation, using a standard 12.5% discount rate. Our valuation is currently restricted to the potential use of ANX-188 in children in the U.S. market, based on market launch in 2016 and peak sales of $85m. An FDA agreement and clarity on the pivotal study design is crucial and could lead to a re-rating. Cash of $46m is sufficient for two years, assuming the trial starts by year end.

bron:
seekingalpha.com/article/625921-2-pha...
[verwijderd]
0
[verwijderd]
0
From a technical perspective, ANX is jumping higher here with monster volume, and this stock has started to flirt with breakout territory above some near-term overhead resistance at 61 cents.

Traders should now look for long-biased trades if ANX can manage to take out its 200-day moving average of 67 cents with high volume. Look for a sustained move or close above 67 cents with volume that's near or above 286,871 shares. If we get that action soon, a much bigger breakout will trigger once ANX takes out more past resistance at 69 to 72 cents with volume. Any high-volume move over those levels will set this stock up to trend back towards $1 to $1.16 in the near future. It's very possible ANX could hit $1.40 if it triggers high-volume moves over 72 cents and then $1.16.

data.cnbc.com/quotes/ANX
[verwijderd]
0
Daghandelaren pakken hun winsten, volume zeer hoog. Verwacht en hoop dat de stijging doorzet. #zitmeerinhetvat
[verwijderd]
0
"We are excited to present at the Sickle Cell Disease Therapeutics Conference at a time when our product candidate, ANX-188, is poised to commence its Phase 3 clinical study," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "The disease was identified over one hundred years ago, but only one FDA-approved drug is available, and none are available to treat an on-going vaso-occlusive crisis or the underlying ischemia and infarction that reduce the average life expectancy to less than 40 years. Awareness leads to investment, development, and eventually, to new treatments. This conference is an excellent forum to discuss with investors and potential licensing partners the latest advancements for patients suffering with this rare disease."

Read more here: www.sacbee.com/2012/07/26/4662248/adv...

Doniss
0
Ik heb deze on strong watch. Hoge volumes laatste dagen, alleen het is tijd om uit te breken en dat is nog niet gebeurd.
[verwijderd]
0
Als zone 0,85 wordt gebroken dan kunnen we rap omhoog! Aandeel staat op uitbreken mensen, profiteer ervan!

investorshub.advfn.com/boards/read_ms...
[verwijderd]
0
Ik ga er ook vanuit, maar we zullen het zien..

Ik citeer 'the company has no debt and a strong cash position of over $43 million or .90 cents per share'.

Alleen dat is al een mooie zaak. ANX-530 is in het verleden helaas niet gelukt, maar ik verwacht dat het met de ANX-188 nu zeker gaat lukken.. We zullen het zien.. :)
Doniss
0
ANX moet idd 0,83 - 0,85 zone doorbreken, dan kunnen we los!
Daarna de oude weerstanden van september/oktober 2011, dan lijkt de weg vrij richting 2
[verwijderd]
0
quote:

justbigwin schreef op 25 september 2012 21:35:

zei het toch, al 5 cent eraf na mijn post
glazen bol haha... even meer onderbouwen svp.... Anx kan zeker omhoog.. 90 cent per aandeel waard in geld, geen schulden en daarnaast een phase3 med in ontwikkeling.. Biostocks gaan altijd op speculatie omhoog.. Daarnaast technisch zeer interessant.. Vandaag niet gelukt om door de 0.85 te breken.. Kwestie van tijd, komt goed.. Kijk naar Peregrine Pharmaceuticals.. Binnen 3 maanden van 0.54 naar 5 dollar! Anx heeft in het verleden "Exelbine" verknald, ga ervan uit dat ze daar behoorlijk van geleerd hebben.. ANX-188 moet hem gaan worden..Nogmaals kan snel gaan met biostocks, down, maar zeker ook up!
425 Posts, Pagina: « 1 2 3 4 5 6 ... 16 17 18 19 20 21 22 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
878,84  +8,57  +0,98%  14:59
 Germany40^ 18.063,80 +0,82%
 BEL 20 3.873,48 +0,40%
 Europe50^ 4.979,86 +0,83%
 US30^ 38.209,11 +0,22%
 Nasd100^ 17.570,54 +0,81%
 US500^ 5.095,04 +0,99%
 Japan225^ 38.035,55 +0,82%
 Gold spot 2.344,25 +0,52%
 EUR/USD 1,0717 -0,12%
 WTI 84,29 +0,64%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

EBUSCO HOLDING +9,33%
ASMI +6,81%
NX FILTRATION +5,38%
Alfen N.V. +5,27%
Corbion +3,92%

Dalers

IMCD -8,19%
SIGNIFY NV -7,45%
Wereldhave -6,63%
BESI -5,51%
ABN AMRO BANK... -3,94%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront